3758 results about "Coronavirus" patented technology

The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).

The invention discloses an anti-SARS-CoV-2 fully-humanized monoclonal antibody against SARS-CoV-2. The antibody is obtained by screening through a flow sorting-single cell PCR technology, and has a unique CDR partition. The invention further discloses an application of the antibody in preparation of medicines for treating the 2019-coronavirus disease. The monoclonal antibody disclosed by the invention has efficient and specific anti-SARS-COV-2 activity, also has the characteristics of high expression, complete humanization and good stability, and is suitable for industrial production.

The invention discloses humanized single-domain antibodies for a novel coronavirus SARS-CoV-2 and an application of the humanized single-domain antibodies. The invention protects the single-domain antibodies described in any one of SEQ ID No.1 to SEQ ID No.5. Experimental results show that the single-domain antibodies provided by the invention have good affinity with receptor binding domain (RBD)antigens and have high neutralization activity on SARS-CoV-2 pseudovirus. The humanized single-domain antibodies have important scientific significance and application prospect for prevention and clinical treatment of the new coronavirus SARS-CoV-2 and for development of diagnostic reagents of the new coronavirus SARS-CoV-2.

The invention relates to a preparation method for a vaccine capable of treating and/ or preventing SARS-CoV-2 infection or COVID-19 diseases. The core antigen of the vaccine comprises the RBD (receptor binding zone) fusion protein of the SARS-CoV-2, and a vaccine form comprises an RBD fusion protein subunit vaccine, an RBD fusion protein mRNA vaccine or an RBD fusion protein adenovirus vector vaccine. The above vaccine immunizes an organism, and immune reaction for treating and/ or preventing the SARS-CoV-2 infection can be generated so as to be used for treating and/ or preventing COVID-19. The invention also relates to an RBD fusion gene, the RBD fusion protein, a carrier, a cell, a preparation method, a treatment method or a pharmacy purpose of the SARS-CoV-2.

Provided are compounds, methods and pharmaceutical compositions for treating a host, especially a human, infected with a togavirus, herpes virus and/or coronavirus, and in particular SARS-CoV, cytomegalovirus or varicella-zoster virus. The method in one embodiment comprises administering to that host an effective amount of an anti-togavirus, anti-herpes virus and/or anti-coronavirus phospholipid or a pharmaceutically acceptable salt or prodrug thereof. The phospholipid compound is, e.g., a 3-alkylamido-2-alkoxypropylphosphocholine compound or salt thereof. The compound may be administered alone or in combination and/or alternation with one or more other anti-viral agents.

The invention provides a detection kit of IgM/IgG antibodies of novel coronavirus (SARS-CoV-2), and relates to the technical field of biology. According to the detection kit of IgM/IgG antibodies of novel coronavirus (SARS-CoV-2), the IgM/IgG antibodies of novel coronavirus (SARS-CoV-2) are detected through adoption of a colloidal gold capture method, a colloidal gold indirect method and a colloidal gold double antigen sandwich method, wherein adopted antigens are highly active recombinant antigens which are obtained through fusion expression of N protein fragments and S protein dominant epitope fragments, and colloidal gold is labeled indirectly, so that steric hindrance is reduced, and the activity, reaction consistency and accuracy of the antigens are increased. Since a sample pad is pretreated, the interference of complex components in a blood sample to a reaction can be reduced greatly, the detection kit has no requirements for instruments during detection, simple and flexible operation, direct and manual interpretation of results and a short test time, the results can be interpreted in only 15 minutes, and the test results are accurate.

The invention discloses a colloidal gold kit for jointly detecting coronavirus IgM/IgG antibody, and a preparation method thereof, and relates to the field of biological medicine. Whether anti-novel coronavirus nucleocapsid protein IgM antibody and/or anti-novel coronavirus nucleocapsid protein IgG antibody exists in human serum or plasma or not by adopting an antigen-antibody sandwich method anda colloidal gold immunochromatography method principle, the novel coronavirus nucleocapsid protein containing 6xHis mark is marked by applying colloidal gold, thereby forming gold-marked N protein tobe adsorbed on a gold-marked pad, the novel coronavirus nucleocapsid protein containing 6xHis mark is used as an indication marker, the mouse-anti-human u chain monoclonal antibody is coated on the IgM detection line of a NC membrane, the mouse-anti-human IgG monoclonal antibody is coated on the IgG detection line and the mouse-anti 6xHis monoclonal antibody is coated on a quality control line ofthe NC membrane, the qualitative detection of the anti-novel coronavirus nucleocapsid protein IgG antibody is realized, and the colloidal gold kit disclosed by the invention has the advantages of being convenient to use, high in sensitivity and short in detection time.

The invention discloses a coronavirus rapid detection kit based on S protein ligand and ACE2 receptor competitive chromatography. The coronavirus rapid detection kit comprises quantum dot labeled ACE2protein, quantum dot labeled rabbit IgG, recombinant coronavirus spinous process protein S1, goat anti-rabbit IgG polyclonal antibody, an immunochromatographic test strip and other materials. The detection sensitivity is improved through quantum dot fluorescence labeling and multistage coupling amplification signals, the detection specificity is improved and the antibody research and developmentcycle is avoided by utilizing the ligand and receptor binding principle, the kit capable of rapidly detecting coronavirus is provided, and the biosafety in the detection process is guaranteed by establishing a virus inactivation system. The kit disclosed by the invention is suitable for detecting various biological samples and environmental samples such as oral mucosa liquid, respiratory tracts, whole blood, plasma, serum, excrement and the like, and can be applied to rapid detection of coronaviruses taking ACE2 as a receptor, such as SARS-CoV-19, SARS-CoV, HCoV-NL63 and the like.

The invention discloses a novel coronavirus pneumonia (COVID-19) serological diagnosis kit. The kit comprises an S-IgM/IgG test strip and an N-IgM/IgG test strip, the double-antigen quadruple detection kit can be used for simultaneously detecting four indexes of an IgM/IgG antibody for resisting novel coronavirus spinous process protein S and an IgM/IgG antibody for resisting novel coronavirus nucleocapsid protein N in serum of a patient suffering from novel coronavirus pneumonia COVID-19. According to the kit, the detection sensitivity is improved through quantum dot fluorescence labeling andmultistage coupling amplification signals, the detection accuracy is improved through double-antigen quadruple detection, and the biological safety in the detection process is guaranteed by establishing a virus inactivation system. The kit is suitable for whole blood, plasma and serum detection, and can be applied to novel COVID-19 serological diagnosis.

The invention belongs to the technical fields of biochips and diagnostic reagents, and discloses a method for detecting various respiratory viruses, and primers and probes thereof. In the invention, nucleotide sequences of 14 respiratory viruses, namely adenovirus, human metapneumovirus, influenza virus A, influenza virus B, respiratory syncytial virus, bocavirus, rhinovirus, coronavirus (HKU1, NL63 and SARS), and parainfluenza virus (type I, type II, type III and type IV) are analyzed, and corresponding reverse transcription primers, PCR primers and specific probes are designed. Specific gene segments are amplified by reverse transcription and multiple asymmetric PCR methods; a fluorescence-coded microsphere group coupled with the virus specific probes and the PCR amplification product are incubated and hybridized by liquid phase chip technology; and finally the Bio-PlexTM200 is used for detection. The detection method has the advantages of high flux, high specificity and sensitivity, stable results and good repeatability, the detection method is easy to operate, and the detection speed is high.

The invention discloses a fusion protein of a novel coronavirus envelope protein and an application of the fusion protein. The fusion protein (SARS2-RBD-Fc) is obtained by fusing an RBD structural domain of a novel coronavirus envelope protein S with an antibody Fc fragment; and as a subunit vaccine, the fusion protein can induce an organism to generate an efficient neutralizing antibody through nasal drip immunization and intramuscular injection. It indicates that the SARS2-RBD-Fc can be used as a candidate vaccine for preventing and treating new coronavirus infection.

Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

The invention relates to traditional Chinese medicine compositions, and specifically discloses a prescription capable of treating pneumonia caused by 2019-nCoV (a novel coronavirus) infection as wellas application thereof. The prescription capable of treating the pneumonia caused by the 2019-nCoV infection comprises the following traditional Chinese medicine materials as raw materials in parts byweight: 9 parts of ephedra, 6 parts of roasted liquorice roots, 9 parts of apricot kernels, 15-30 parts of raw gypsum, 9 parts of cassia twigs, 9 parts of oriental waterplantain rhizome, 9 parts of zhuling, 9 parts of white atractylodes rhizomes, 15 parts of poria cocos, 16 parts of radix bupleuri, 6 parts of baical skullcap roots, 9 parts of ginger processed pinellia tubers, 9 parts of fresh ginger, 9 parts of aster, 9 parts of common coltsfoot flowers, 9 parts of blackberry lily rhizome, 6 parts of manchurian wildginger, 12 parts of Chinese yams, 6 parts of immature orange fruits, 6 parts of dried orange peel, and 9 parts of wrinkled gianthyssop herb. In combination with symptom manifestation of the pneumonia caused by the 2019-nCoV infection, the invention adopts an optimized and integrated traditional Chinese medicine prescription, thereby achieving synergistic treatment effects. According to current treatment results of diagnosed patients of different ages in many provinces and regions, the prescription capable of treating the pneumonia caused by the 2019-nCoV infection has true curative effects that the response rate is up to 95.12%.

The invention relates to the technical field of biology, and specifically provides a detection kit for a detection kit for antigens of a novel coronavirus (SARS-CoV-2). According to the detection kitprovided by the invention, the antigens of the SARS-CoV-2 are detected by virtue of a colloidal gold double antibody sandwich method, and two monoclonal antibodies and colloidal gold are mixed for labeling, so that a detection result of the antigens of the SARS-CoV-2 is accurate and high in sensitivity, and meanwhile, the detection rate can be remarkably increased. According to the detection kit,a blank in immunological detection of the SARS-CoV-2 is filled up, and field detection can be realized without a detection instrument, so that the time and the labor are saved, and operation is flexible.

Therapeutic antimicrobial compositions and methods for providing enhanced immediate and residual anti-viral and antibacterial efficacy against rhinovirus, rotavirus, coronovirus, respitory syricytial virus, Gram-positive bacteria, Gram-negative bacteria and combinations thereof. More specifically, therapeutic antimicrobial compositions comprising an organic acid or organic acid mixture and a short-chain anionic surfactant having at least one of a large head group; a branched alkyl chain and an unsaturated alkyl chain, and therapeutic methods of use thereof.

The invention provides a novel coronavirus ORF1ab gene nucleic acid detection kit, and particularly discloses a kit for detecting the ORF1ab gene of the novel coronavirus and a method thereof, which have extremely high sensitivity and specificity.

The invention relates to the technical field of medical biology, and specifically discloses a novel coronavirus (SARS-COV-2) spike protein binding molecule and applications thereof. The binding molecule can specifically bind the spike protein of SARS-COV-2 and includes at least one immunoglobulin single variable structural domain. The provided binding molecule can specifically bind the SARS-COV-2-Spike protein and effectively block the binding of the SARS-COV-2-Spike protein and human cell ACE2 receptors, so that the infection process of the SARS-COV-2 on cells can be further blocked, and theinfection and amplification of the SARS-COV-2 can be inhibited.

The present invention belongs to the field of biomedicine, and relates to polypeptides capable of inhibiting human coronavirus infections, particularly to polypeptides capable of inhibiting human coronavirus infections in a broad spectrum manner, and applications thereof. According to the present invention, the polypeptides capable of providing broad spectrum inhibition effects for infections caused by more than 2 human coronaviruses are provided based on the conservation property of the S2 region of a coronavirus S protein and the similar fusion mechanism; the test results show that the polypeptides can achieve the commonality of the human coronavirus, ie., the similar HR region and the same fusion mechanism mediated by the coronavirus S protein so as to provide a series of HCoV-EK polypeptides, wherein the polypeptides provide good inhibition effects for currently popular human coronaviruses, and further provide good inhibition activity for SARS virus (RsSHC014-CoV or RsW1V1-CoV) possibly infecting human; and the polypeptides of the present invention can provide the prevention and treatment candidate drug for the currently popular human coronaviruses and the novel human coronavirus possibly emerging in the future.

The invention discloses a fluorescence immunochromatography device for detecting a novel coronavirus COVID-19 and a using method of the fluorescence immunochromatography device. The fluorescence immunochromatography device disclosed by the invention is high in sensitivity and strong in specificity, the accuracy is high, the detection sensitivity can reach 10pg/ml, the detection speed is high, theoperation is simple, the device is portable, the requirement for personnel is low, the operation of professionals is not needed, the detection cost is low, the device can be applied to preliminary screening of various places such as hospitals, airports, customs and disease control centers, the detection time (10-15 min) is short, a simpler, more convenient and faster field detection means is provided for suspected patient investigation and asymptomatic infected person screening, and therefore epidemic spreading is prevented as soon as possible.

The invention discloses a nucleic acid composition, a kit and a method for detecting 2019 novel coronaviruses, belonging to the technical field of biology. The nucleic acid composition disclosed by the invention comprises at least one selected from the group consisting of a first nucleic acid combination and a second nucleic acid combination, wherein the first nucleic acid combination comprises nucleic acids as shown in SEQ ID NO.4-6, and the second nucleic acid combination comprises nucleic acids as shown in SEQ ID NO.7-9. When the nucleic acid composition, the kit or the method provided by the invention is used for detecting the 2019 novel coronaviruses, higher sensitivity and higher specificity are achieved.